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A B S T R A C T
Purpose: Use of concomitant medicines (CMs) is a common practice in people with epilepsy, as
comorbidity in this group is frequent. Comedication, especially if it is self-administered, may pose
signiﬁcant hazards due to potential interactions. Some attention has been given to use of CMs in older
patients with epilepsy but the CM habits of younger patients are much less known. The purpose of this
study was to determine annual frequency of use, kind and cost of CMs in patients with epilepsy.
Material and methods: The 12-month prospective multicentre study included 772 patients with a mean
age of 27.4 yrs and a mean epilepsy duration of 12.5 yrs. Data on patient characteristics and treatment
were collected during consecutive ﬁve visits. All CMs were classiﬁed according to the ATC system.
Results: Of the 772 patients, 472 (61.1%) used at least one CM (3.4 drug/patient). OTC drugs constituted
nearly 2/3 of all CMs. More women then men took CMs (p < 0.002). The patients taking CMs were
signiﬁcantly older, had longer duration of epilepsy, more frequent comorbidities, and more seizures than
patients not receiving any CM. Alimentary tract and metabolism drugs (28.9%), nervous system drugs
(19.8%) and cardiovascular system drugs (11%) were the ones most commonly used. The annual cost of
CMs was 76011.9 s PPP (mean cost/patient – 161.0 s PPP).
Conclusions: The results conﬁrm that patients with epilepsy, regardless of age, take commonly CMs.
Physicians should be more aware of this practice.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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In addition to antiepileptic drugs (AEDs), people with epilepsy
also take concomitant medicines (CMs) for a number of reasons.
This is mainly due to concomitant diseases which are frequent in
this group. Population studies indicate that people with epilepsy
have a two- to ﬁve-fold increase in occurrence of most chronic
psychiatric and somatic conditions compared with the general
population.1–3 These include such conditions as migraine, cere-
brovascular and cardiovascular disorders, gastrointestinal disor-
ders, depression, anxiety, and personality disorders. CMs used for
these conditions often have clinically signiﬁcant drug-drug
interactions which occur with agents that interact with the
cytochrome P450 pathway, including AEDs.4 The high prevalence
of comorbidities and the ensuing need to use CMs requires
increased access to healthcare and substantially increases its
costs.5* Corresponding author at: Epilepsy Diagnostic and Therapeutic Center,
Foundation of Epileptology, Wiertnicza 122 Str., Warsaw, Poland.
Tel.: +48 602 216 032.
E-mail address: beata.m.zwolinska@gmail.com (B. Majkowska-Zwolin´ska).
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doi:10.1016/j.seizure.2011.06.015The second reason for CM use by people with epilepsy is easy
access to over-the-counter (OTC) complementary medicines.
According to various studies, this applies to more than 30% of
patients.6–8 About one-fourth use them speciﬁcally for their
epilepsy9 and the majority use them for general health conditions.6
Vitamins and herbal medicines are one of the most common forms
of complementary medicines. However, some of the most popular
herbal remedies are known to act on the cytochrome P450 system,
with potential effects on AED levels, and some of them exhibit
proconvulsive effects.10 Because fewer than 40% of patients report
use of these substances to their physicians, the consequences are
often hazardous.10 Comedication is especially problematic in older
patients and it has received appropriate attention. Less informa-
tion is available, however, about medication habits and their costs
in younger patients with chronic epilepsy.
This paper is complementary to a prospective multicentre project
estimating global annual costs of epilepsy in Poland in 2006.11,12
1.1. Purpose
The purpose of this prospective study was to determine
frequency of use, kind and cost of CMs in patients with epilepsy
during a 1-yr observation period.vier Ltd. All rights reserved.
Fig. 1. Antiepileptic drugs (AEDs) used in 767 patients with chronic epilepsy.
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The prospective study was conducted in 18 neurology and
epilepsy centres in Poland. The recruitment period was from July
2005 until December 2006. The 12-month observation period was
until December 2006. Of the 969 patients with established epilepsy
enrolled, 772 (79.7%) underwent complete 1-yr observation.
Patients who have had 3, 6 or 9-month observation were not
included in this analysis. Demographic and treatment character-
istics of the patients are presented in Table 1. Data on clinical
characteristics and CMs were collected in a standardized way, based
on ﬁve questionnaires. The ﬁrst questionnaire was used to collect
baseline data during the ﬁrst visit and the next four were completed
quarterly by the neurologists during patients’ consecutive visits.
Fig. 1 presents the number of AEDs administered in 767 patients (in
ﬁve patients no AEDs were administered due to seizure remission).13
AEDs were divided into enzyme-inducing AEDs including carba-
mazepine (CBZ), phenytoin (PHT), primidon (PRM) and phenobar-
bital (PB), and non-inducing AEDs (all other AEDs used).
CMs were deﬁned as any no-AED medicines used sporadically
or chronically by patients during the 1-yr observation period. The
use of more than 120 tablets of any medicines per year was
considered as chronic treatment. Acute or sporadic use referred to
use of less than 120 tablets. All medicines were classiﬁed accordingTable 1
Demographic characteristics and treatment of 772 patients with epilepsy.
Gender Female – 420
Male – 320
Age Mean – 27.4, median – 25.0;
range 0.5–82.0 yrs
Age of seizure onset Mean – 14.8, median – 11.0;
range 0.5–70.0 yrs
Duration of epilepsy Mean – 12.5, median – 9.0;
range 1.0–62.0 yrs
Mean no of seizure/patient 1.55
Focal onset seizure 76.8%
Primary generalized seizures 21.4%
Unclassiﬁed seizures 1.8%
Mean no of AEDs/patient 1.99
AEDs – antiepileptic drugs.to the Anatomical Therapeutic Chemical (ATC) Classiﬁcation
System.14 In this paper we took into consideration 1st level (main
groups) and 2nd level (pharmacological/therapeutic subgroups)
codes for all medicines, and 3rd and 5th level codes for the most
frequently used medicines (chemical/pharmacological/therapeu-
tic subgroups and chemical substance), respectively. The number
of patients receiving medicines from the main groups (level 1)
corresponds to the number of patients who took any drug from the
main groups. The number of patients using drugs from subgroups
(level 2) may be higher than the number given in main groups
(level 1) because some patients took more than one drug from
different subgroups.
CMs included both prescription medicines and OTC drugs.
CM calculations of costs of annual treatment were based on
number of packages of medicines prescribed by the physician or
bought by patients themselves. Costs for each individual patient
were calculated in Polish currency (PLN) and converted, for sake of
comparison, to Euro Purchasing Power Parity PPP (s PPP); the
conversion rate for 2006 was 2.26368 PLN to 1 s PPP.
Statistical analysis for comparison of qualitative data (sex,
presence of seizure) was performed by means of the x2 test.
Quantitative data (age, duration of epilepsy) were analyzed with
either the t-Student test or the Mann–Whitney test, depending on
the normality of distribution assumption.
The cost–age relationship was analyzed by means of linear
regression and correlation methods. All tests were two-tailed and
the level of signiﬁcance was a = 0.05.
The Commission for Bioethics at the District Chamber of
Physicians in Warsaw approved the project on the 30 June 2005;
decision nr 27/05/. The work has been carried out in accordance
with The Code of Ethics of the World Medical Association
(Declaration of Helsinki).
3. Results
3.1. Patients on CMs
Of the 772 patients with epilepsy, 472 (61.1%) used 1607 drugs
other than AEDs during 1 yr of observation (3.4 drug/patient). Of
1607 medicines 922 (57.4%) were used as an acute or sporadic
Table 2
Number and costs (percent) of concomitant medicines (CM) used in 472 patients with epilepsy during 1 yr [classiﬁed according to Anatomical Therapeutic Chemical (ATC)
Classiﬁcation System].








A Alimentary tract and metabolism 465 (28.9) 269 (57.0) 16194.4 (21.3) 60.2
N Nervous system 318 (19.8) 205 (43.4) 24009.7 (31.6) 117.1
C Cardiovascular system 178 (11.1) 84 (17.8) 10757.3 (14.2) 128.1
J Antiinfectives for systemic use 137 (8.5) 104 (22.0) 2082.5 (2.7) 20.0
B Blood and blood forming organs 131 (8.2) 114 (25.1) 2657.8 (3.5) 25.5
M Muscolo-skeletal system 112 (7.0) 71 (15.0) 2316.1 (3.1) 32.6
R Respiratory system 111 (6.9) 79 (16.7) 8689.1 (11.4) 110.0
G Genito-urinary system and sex hormones 61 (3.8) 44 (9.3) 5215.4 (6.7) 118.5
D Dermatologicals 41 (2.5) 34 (7.2) 1192.8 (1.6) 35.1
H Systemic hormonal preparations 23 (1.4) 18 (3.8) 810.5 (1.1) 45.0
S Ophtalmologicals 17 (1.1) 12 (2.5) 880.2 (1.2) 73.4
V Other non-therapeutic products 9 (0.6) 9 (1.9) 423.7 (0.6) 47.1
L Antineoplastic and immunomodulating agents 4 (0.2) 4 (0.8) 782.4 (1.0) 195.6
Total 1607 (100) 76011.9 (100) 161.0
a The number of patients does not add to 100%, because some patients took CM from more than one ATC group, PPP –Purchasing Power Parity.














A (n=269) C  (n=84) N (n=205)
Fig. 2. Age related distribution of the three most frequently used concomitant
medicines groups A - Alimentary Tract and Metabolism, C - Cardiovascular System
and N - Nervous System.
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than men used CMs: 277 (58.7%) vs. 195 (41.3%) (p  0.002). Mean
age of patients was 31.2 yrs in the group with CMs and 21.0 yrs and
in the group without CMs (p < 0.0001). The mean duration of
epilepsy was longer in the group of patients receiving CMs (14.1
yrs) than in the group of patients not receiving CMs (9.9 yrs)
(p < 0.0001). Comparison of presence of seizures during 1 yr
showed that there were more patients with seizures in the group
with CMs – 341 (69.7%) than in the group without CMs – 148
(30.3%), p < 0.001.
At least one concomitant disorder was present in 330 out of 772
patients (42.7%). The most frequent chronic conditions were
mental retardation, mental and behavioural disorders and
hypertension. Among patients taking CMs, there were more
patients with chronic concomitant diseases (any type) – 245
(74.2%) than among patients not taking CMs – 85 (28.3%),
p < 0.0001.
All 472 patients with CMs were treated with 994 AEDs (2.1 AED
per patient). Out of this group, 200 (42.4%) received enzyme-
inducing AEDs in comparison with 113 patients (37.7%) out of 300
who did not take CMs (p = 0.22).
3.2. Use of CMs
Fourteen groups of drugs used by the patients, classiﬁed
according to the ATC system, are listed in Table 2. The most
frequently used CMs belonged to the alimentary tract and
metabolism group (A) – 465 (28.9%) CM, nervous system group
(N) – 318 (19.8%) CM and cardiovascular system group (C) – 178
(11%) CM. Drugs from other groups accounted for less than 10% each.
3.2.1. Main group A medicines
CMs from group A were taken by 269 patients (57.0%). Table 3
presents the most common drugs from group A: vitamins (50.1%),
mineral supplements (17.4%), drugs for acidic disorders (8.4%),
functional gastrointestinal disorders (7.0%), and bile and liver
therapy (6.5%). Together these drugs accounted for 90% of all drugs
from group A.
There were no signiﬁcant age and gender differences in number
of patients between patients taking drugs from group A and those
not taking drugs.
3.2.2. Main group N medicines
The second most frequently used group N consisted of
psychoanaleptics (36.8%), analgesics (31.1%) and psycholeptics
(29.8%), taken by 95, 81 and 73 patients, respectively. Other drugs
constituted 2.2% (Table 3).Among the psychoanaleptics, nootropic drugs and agents used
for ADHD constituted 56.4% and antidepressants – 43.6%. The latter
group included new class drugs – selective serotonin reuptake
inhibitors, selective serotonin reuptake enhancers, serotonin–
nonepinephrine reuptake inhibitors (67.3%) and older class drugs –
tricyclic antidepressants and monoamino oxidase inhibitors
(37.7%).
Psycholeptics comprised antipsychotics (51.6%) and anxiolytics
and sedatives (48.4%). Antipsychotics included typical (67.3%) and
atypical (32.7%) drugs.
There were no gender or age differences in CM use between
patients taking and not taking drugs from group N.
3.2.3. Main group C medicines
Among drugs from group C, taken by 84 patients (17.8%), the
following were used most frequently: agents acting on the renin–
angiotensin system (25.8%), beta blocking agents (17.9%), lipid
modifying agents (15.7%), diuretics (14.6%) and calcium channel
blockers (9.5%). These drugs constituted more than 80% of all drugs
from group C (Table 3).
In patients treated with cardiovascular drugs, the mean age (45.6
yrs) was signiﬁcantly greater than in the remaining group (28.1 yrs),
p > 0.0001. Use of those medications increased with age (Fig. 2).
There were no gender differences in use of CM between patients
taking and not taking medicines from group C.
Table 3
Use and costs of concomitant medicines (CM) in 472 patients with epilepsy (ATC classiﬁcation, 1st and 2nd level).
ATC groups 1st level ATC subgroups 2nd level No of CM use (%) No of patientsa (%) Cost in s PPP (%)
A A 11 Vitamins 237 (51.0) 190 (40.2) 6911.7 (42.7)
A 12 Mineral supplements 81 (17.4) 70 (14.8) 1713.4 (10.6)
A 02 For acid related disorders 39 (8.4) 30 (6.3) 2076.8 (12.8)
A 03 For gastrointestinal disorders 33 (7.0) 29 (6.1) 892.5 (5.5)
A 05 Bile and liver therapy 30 (6.5) 24 (5.1) 1873.7 (11.6)
Others 45 (9.7) 35 (7.4) 2726.3 (6.8)
B B 03 Antianemics 96 (73.3) 86 (18.2) 1333.3 (50.2)
B 01 Antithrombotics 29 (21.1) 24 (5.1) 1029.8 (38.7)
Others 6 (5.6) 6 (1.3) 294.8 (11.1)
C C 09 Agents acting on the renin–angiotensin system 46 (25.8) 42 (8.9) 3651.9 (34.0)
C 07 Beta blocking agents 32 (18.0) 27 (5.7) 1162.9 (10.8)
C 10 Lipid modifying agents 28 (15.7) 22 (4.7) 2132.9 (19.8)
C 03 Diuretics 26 (14.6) 25 (5.3) 912.8 (8.5)
C 08 Calcium channel blockers 17 (9.5) 16 (3.4) 949.9 (8.8)
C 05 Vasoprotectives 11 (6.2) 10 (2.1) 730.2 (6.8)
C 01 Cardiac therapy 9 (5.0) 8 (1.7) 378.1 (3.5)
Others 9 (5.0) 8 (1.7) 838.5 (7.8)
D D 07 Corticosteroids 20 (48.8) 18 (3.8) 913.4 (76.6)
D 08 Antiseptics and disinfectans 4 (9.8) 4 (0.8) 13.5 (1.1)
D 01 Antifungals 3 (7.3) 3 (0.6) 42.8 (3.6)
D 10 Anti-acne preparations 3 (7.3) 2 (0.4) 27.1 (2.3)
Others 11 (26.8) 10 (2.1) 196.0 (16.4)
G G 03 Sex hormones 42 (68.9) 35 (7.4) 3247.4 (62.3)
G 04 Urologicals 7 (11.5) 6 (1.3) 1544.7 (29.6)
G 01 Ginecological antiinfectives 7 (11.5) 7 (1.5) 57.3 (1.1)
Others 5 (8.2) 5 (1.1) 366.0 (7.0)
H H 03 Thyroid therapy 16 (69.6) 11 (2.3) 389.7 (48.1)
H 02 Corticosteroids 6 (26.0) 6 (1.3) 241.8 (29.8)
Others 1 (4.3) 1 (0.2) 179.0 (22.1)
J J 01 Antibacterials 118 (86.1) 91 (19.3) 1810.3 (86.9)
J 07 Vaccines 16 (11.7) 15 (3.2) 162.2 (7.8)
Others 3 (2.2) 3 (0.6) 110.0 (5.3)
L L 04 Immunosuppressants 2 (50.0) 2 (0.4) 286.4 (36.6)
L 03 Immunostimulants 1 (25.0) 1 (0.2) 21.7 (2.8)
L 02 Endocrine therapy 1 (25.0) 1 (0.2) 474.3 (60.6)
M M 01 Antiinﬂamatory and antirheumatics 81 (72.3) 60 (12.7) 1226.6 (53.0)
M 03 Muscle relaxant 16 (14.3) 15 (3.2) 530.5 (22.9)
M 02 Products for joint and muscular pain 10 (8.9) 9 (1.9) 109.7 (4.7)
Others 5 (4.5) 4 (0.8) 449.3 (19.4)
N N 06 Psychoanaleptics 117 (36.8) 95 (20.1) 11891.6 (49.6)
N 02 Analgesics 99 (31.1) 81 (17.2) 842.2 (3.5)
N 05 Psycholeptics 93 (29.2) 73 (15.5) 10691.2 (44.4)
Others 7 (2.2) 7 (1.5) 584.7 (2.4)
R R 06 Antihistamines 33 (29.7) 29 (6.1) 771.7 (8.9)
R 05 Cough and cold preparations 33 (29.7) 29 (6.1) 254.9 (2.9)
R 03 For obstructive airways diseases 27 (24.3) 15 (3.2) 7367.5 (84.8)
R 01 Nasal preparations 11 (9.9) 10 (2.1) 187.2 (2.2)
R 02 Throat preparations 7 (6.3) 7 (1.5) 107.8 (1.2)
S S 01 Ophtalmologicals 15 (88.2) 10 (2.1) 877.2 (99.7)
S 03 Ophtalmologicals and otologicals 2 (11.8) 2 (0.4) 3.0 (0.3)
V V 06 General nutrients 8 (88.9) 8 (1.7) 216.1 (51.0)
V 07 All other non-therapeutics 1 (11.1) 1 (0.2) 207.6 (49.0)
Total 1607 76011.9
a The number of patients using CM from each main group does not correspond to number given in Table 2, as some patients took more than one drug from different
subgroups., PPP – Purchasing Power Parity.
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contraceptives (OCs). All of those OCs contained <50 mg of estrogen.
The most commonly used drugs in level 2 groups were:
vitamins (14.7%), antibacterials (7.3%), psychoanaleptics (7.2%),
analgesics (6.1%), antiemetics (6.0%), psycholeptics (5.9%), and
mineral supplements (5.0%). The other 59 groups of drugs
accounted for less than 5% of use each.
Of the all drugs, the most frequent single medicines (5th level of
ATC classiﬁcation) were vitamin B6 (117; 7.3%) and folic acid (69;
4.3%). All other single drugs did not exceed 1.5% of use each.
3.3. Cost of drugs
Total annual cost of CMs for 472 patients with epilepsy was
76011.9 s PPP (Tables 2 and 3). Mean annual cost per patient was
161.0 s PPP (median – 70.8, range from 1.1 to 2400.7 s PPP).Use of nervous system drugs contributed the most to annual
costs and amounted to 24009.7 s PPP (31.6%), mean cost per
patient – 117.1 s PPP. Drugs from group A, mainly vitamins, were
second – 16194.4 s PPP (21.3%), mean per patient – 60.2 s PPP,
followed by cardiovascular drugs – 10757.3 s PPP (14.2%), mean –
128.1 s PPP and respiratory system drugs – 8689.1 (11.4%), mean –
110.0 s PPP. Drugs from those four groups constituted 78.5% of all
CM costs.
There was no signiﬁcant gender difference in mean costs of CM:
363.8 s PPP for males and 365.1 s PPP for females.
Linear regression analysis revealed a positive correlation
between costs and patients’ age, correlation coefﬁcient (r = 0.2);
there was no correlation between costs and duration of epilepsy.
Mean annual cost of CMs was higher in persons with chronic
concomitant diseases – 237.6 s PPP than in persons without such
diseases – 78.4 s PPP (p < 0.0001).
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Two hundred and ninety patients used 580 OTC drugs, mean 2.0
per patient. They constituted 61.4% of those who used any CM. The
most common groups of OTC were vitamins (40%), analgesics
(15.2%), mineral supplements (11.4%), liver protectors (4.6%), and
cold medicines (4.6%). They accounted for 75.8% of all OTC drug
usage.
The overall cost of OTC was 13924.5 s PPP (18.3% of cost of all
CM), mean cost per patient – 48.0 s PPP. Of all OTC, the cost of CM
from group A constituted 78.5%. In this group, vitamins, liver
protectors and mineral supplements constituted 92.8%.
Patients pay the full price of OTC drugs in Poland. Prescription
drugs are either partially reimbursed or fully paid by patients.
Patients covered 53208.3 s PPP (70%) of all CM costs.
4. Discussion
4.1. Use of CMs
Our data conﬁrm the widespread use of CMs in patients with
chronic epilepsy. These patients take both drugs used on a short-
term basis and maintenance therapy. The mean number of CMs
was 3.4 per patient and 2.08 for the 772-patient group. The
material comprises mostly young and middle-aged adults with a
fairly small representation of old people (mean age – 27.4 yrs;
median – 25.0) and therefore a smaller number of CMs could be
expected than in older patients with epilepsy. However, if AEDs
were added, the mean number for the whole group would be 4.07,
which is not drastically less then the mean number of CMs and
AEDs used by patients with epilepsy in nursing homes – 5.6.15
Therefore, the problem of potential interactions seems to be
common and not limited only to the oldest population. More than
40% of patients taking CMs also received enzyme-inducing AEDs
which may reciprocally interfere with drug metabolism.
Almost 2/3 of all the CMs in our group were OTC drugs. Many of
them, like vitamins, mineral supplements, and herbal prepara-
tions, are self-administered without the physician’s knowledge6
and are potentially proconvulsive or harmful. It is worth noting
that the most common reason why doctors are not aware of this is
that they do not ask.8
Generally, CMs were taken signiﬁcantly more frequently by
woman than men (58.7 vs. 41.3%); a similar pattern was found in
the general population in Poland, i.e. 61% vs. 46%.16 However, no
signiﬁcant gender differences in use were found when three major
groups of CMs, alimentary, nervous and cardiovascular system,
were analyzed separately.
As it could be expected, the patients taking CMs were
signiﬁcantly older, had longer duration of epilepsy, more frequent
concomitant diseases, and more seizures than patients not
receiving any CM.
The most common medicines were vitamins, followed by
psychotropic and cardiac medications. Those two latter groups
were also found to be most frequently administered in older
patients with epilepsy in nursing homes.15
4.1.1. Vitamins
Vitamins were the most commonly used CM in the study group
(14.7% of use), taken by 40.2%, and together with mineral
supplements, by 55%. Vitamins and mineral supplements were
also the most frequently taken medicines in the general population
in Poland – 20% of adults and 49.4% of children <15 yrs.16 Of all the
CMs, the single most frequently used drugs were vitamin B6 (7.3%)
and folic acid. In the past it was customary to administer vitamin B6
with then used AEDs, such as phenytoin and its derivatives, to
protect from leukopenia. This still may be the habit amongneurologists and patients in Poland although phenytoin use is now
extremely rare. The more general question now is the rationale for
the use of such quantities of vitamin and mineral supplements,
especially in this rather young group of patients, a habit which is
contributing relevantly to their personal expenses.
4.1.2. Psychotropic drugs
Psychiatric disorders occur more frequently in patients with
epilepsy than in the general population.2 Physicians are often
reluctant to use psychotropic medications in epileptic patients
with psychiatric disorders because of the potential risk of lowering
the seizure threshold. Several pharmacokinetic and pharmacody-
namic interactions, often with important clinical consequences,
between antidepressants, antipsychotics and AEDs are known. AED
inducers increase the clearance of all the antipsychotics, which
may require dosage adjustment.17 In our material, psychoanalep-
tics and psycholeptics constituted 13.1% of all CMs used by 35.6% of
patients and as a group of drugs used for nervous system disorders
were the second according to frequency of use. In older patients
with epilepsy, these are the drugs most frequently used as
comedication.15,18
Antidepressant, neuroleptic and anxiolytic drugs are by far the
most frequently prescribed drugs in patients with mental
retardation. Among our patients who were using CMs, intellectual
impairment (in various degrees, mostly mild) occurred in quite a
large percentage, i.e. in 15.0% of patients.19 These patients are
characterized by an increased incidence of comorbidity, often with
psychiatric disorders which may require treatment with other
medicines. As a group, these patients may be particularly
vulnerable to problems associated with polytherapy.20 From a
practical point of view, it is important to consider the potential
effect of CMs (mostly sedatives) on cognitive functioning, often
falsely suggesting negative AED effects.
4.1.3. Cardiovascular drugs
Cardiovascular drugs were the third most commonly used
drugs and among those used most frequently were hyperten-
sives. The use of these medicines increased with age, as
cardiovascular diseases are more frequent in the older popula-
tion. Hypertension is the most frequent disease in the general
population in Poland16 and also the most frequent somatic
disorder in persons with epilepsy in our material. Generally,
enzyme-inducing AEDs enhance the metabolic clearance of
several cardiovascular agents with a consequent reduction in
their plasma levels and therapeutic efﬁcacy. The most relevant
interactions are interactions with calcium channel blockers and
warfarin. In fact, in the case of nimodipine, the decline of plasma
concentration may be up to sevenfold.21 Conversely, interactions
involving inhibition of AEDs by concomitantly administered
cardiovascular drugs may also be important and may cause toxic
effects.22
4.1.4. Other CMs
Many other less frequently used CMs may exhibit clinically
important interactions with AEDs. For example, AEDs and
hormones have a bidirectional interaction that can impair the
efﬁcacy of contraceptive hormone treatments and the efﬁcacy of
AEDs.23 OCs are prescribed for 16.7% of fertile age women with
epilepsy.24 In our group, the percentage of sex hormone use
(mostly OCs) was smaller (7.4%), it was also smaller in comparison
with the general population in Poland.25 However, use of OCs in
Poland remains one of the smallest in Europe.26 All the OCs used
contained <50 mg of estrogen with the potential of important
interaction with some AEDs.
Antimicrobials are the other example of possible interference
with AED metabolism.22 Nearly 20% of patients in the material
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metabolism and is potentially toxic.
4.2. Cost of CMs
The mean annual cost of CM per patient was 161.0 s PPP with a
wide spread from 1.1 to 2400.7 s PPP. It was substantially lower
then the mean annual cost of AEDs per patient – 1019.8 s PPP.11
However, due to the reimbursement system, in case of AEDs,
patients paid out of their pocket nearly 8% of all expenses, and in
case of CM, patients covered 70% of all CM costs. This is a relevant
personal expense for the patients who are often unemployed and
use social care beneﬁts.
5. Summary and conclusions
 Patients with epilepsy, regardless of age, take commonly CMs.
Nearly 2/3 of patients with epilepsy took at least one CM (3.4
drug/patient) during the 1-yr observation period.
 More women than men took CMs. The patients taking CMs were
signiﬁcantly older, had longer duration of epilepsy, more
frequent concomitant diseases, and more seizures than patients
not receiving any CM.
 The most frequently used drugs were vitamins and mineral
supplements, followed by psychotropic and cardiovascular drugs.
 OTC drugs constituted nearly 2/3 of all CMs.
 The mean annual cost of CMs per patients was much smaller in
comparison with the cost of AEDs but was still a relevant
personal expense.
 Consideration for the potential interactions and consequences of
the common use of CMs, especially OTC drugs, in patients with
epilepsy should urge physicians to pay more attention to this issue.
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